ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sustained Release Injectables Report 2021: Major Factors Driving Sustained Release Injectable Drug Demand - ResearchAndMarkets.com

November 5, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Nov 5, 2021--

The “Sustained Release Injectables” report has been added to ResearchAndMarkets.com’s offering.

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing.

ADVERTISEMENT

Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

What You Will Learn

  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the major factors driving sustained release injectable drug demand?
  • What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
  • In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Key Topics Covered:

ADVERTISEMENT

  • Executive Summary
  • Injectable Drug Market Dynamics
  • The Trend toward Self-Administration
  • Injectable Drug Formulation Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers
  • Market Factors
  • Competitive Landscape
  • Risk Factors
  • Sustained Release - Branded Formulation Technologies
  • Biodegradable Polymers
  • Branded SR Formulation Technologies
  • Physical Process Control Methods
  • Sustained Release Injectables - Development Factors
  • Formulation Factors
  • Stability
  • Lyophilization
  • Packaging
  • Administration Factors
  • SR Injectables - Product Analysis & Market Sector Forecasts
  • Addiction
  • Naltrexone
  • Diabetes
  • Exenatide
  • Infectious Disease
  • Interferon
  • Hormone Deficiency
  • Estradiol
  • Somatropin
  • Testosterone
  • Metabolic Diseases
  • Acromegaly
  • Lanreotide
  • Octreotide
  • Neurology
  • Aripiprazole
  • Fluphenazine
  • Haloperidol
  • Paliperidone
  • Olanzapine
  • Risperidone
  • Oncology
  • Leukemia
  • Vincristine
  • Lymphoma
  • Cytarabine
  • Prostate
  • Goserelin
  • Leuprolide
  • Triptorelin
  • Pain Management
  • Bupivacaine
  • Reproductive Health
  • Endometriosis
  • Company Profiles

Companies Mentioned

  • Alkermes
  • Amylin
  • AntriaBio
  • Ascendis Pharma
  • AstraZeneca
  • Aurobundo
  • Avadel
  • Biomarin
  • Camurus
  • Critical Pharmaceuticals
  • DURECT
  • Eli Lilly Enzon
  • Ipsen
  • Janssen
  • NanOlogy
  • Novartis
  • Oakwood Laboratories
  • PharmaSophia
  • Pacira
  • PhaseBio Pharmaceuticals
  • Recipharm AB
  • Roche
  • Sanofi
  • Taiwan Liposome Company
  • Xbrane Biopharma
  • Talon
  • Octoplus
  • Midatech
  • MedinCell

For more information about this report visit https://www.researchandmarkets.com/r/ol811n

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211105005427/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL OTHER TECHNOLOGY TECHNOLOGY CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 11/05/2021 06:20 AM/DISC: 11/05/2021 06:21 AM

http://www.businesswire.com/news/home/20211105005427/en